Progress in the Application of Drugs for the Treatment of Multiple Sclerosis
Open Access
- 13 July 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 724718
- https://doi.org/10.3389/fphar.2021.724718
Abstract
Multiple sclerosis (MS) is an autoimmune and chronic inflammatory demyelinating disease of the central nervous system (CNS), which gives rise to focal lesion in CNS and cause physical disorders. Although environmental factors and susceptibility genes are reported to play a role in the pathogenesis of MS, its etiology still remains unclear. At present, there is no complete cure, but there are drugs that decelerate the progression of MS. Traditional therapies are disease-modifying drugs that control disease severity. MS drugs that are currently marketed mainly aim at the immune system; however, increasing attention is being paid to the development of new treatment strategies targeting the CNS. Further, the number of neuroprotective drugs is presently undergoing clinical trials and may prove useful for the improvement of neuronal function and survival. In this review, we have summarized the recent application of drugs used in MS treatment, mainly introducing new drugs with immunomodulatory, neuroprotective, or regenerative properties and their possible treatment strategies for MS. Additionally, we have presented Food and Drug Administration-approved MS treatment drugs and their administration methods, mechanisms of action, safety, and effectiveness, thereby evaluating their treatment efficacy.Funding Information
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China
- National Science and Technology Major Project
This publication has 136 references indexed in Scilit:
- Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 yearsMultiple Sclerosis Journal, 2012
- Treatment of neuromyelitis optica: an evidence based reviewArquivos de Neuro-Psiquiatria, 2012
- The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational studyBMC Neurology, 2011
- Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal modelBrain, 2011
- Lights and Shadows of Cyclophosphamide in the Treatment of Multiple SclerosisAutoimmune Diseases, 2011
- Phase III dose‐comparison study of glatiramer acetate for multiple sclerosisAnnals of Neurology, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- Mitoxantrone: benefits and risks in multiple sclerosis patientsNeurological Sciences, 2009
- Diagnosis and treatment of multiple sclerosisActa Neurologica Scandinavica, 2008
- Cyclophosphamide for multiple sclerosisEmergencias, 2007